Clene (NASDAQ:CLNN) Major Shareholder Sells $24,770.02 in Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 3,938 shares of the company’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $6.29, for a total transaction of $24,770.02. Following the sale, the insider directly owned 753,562 shares in the company, valued at approximately $4,739,904.98. The trade was a 0.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The stock was sold at an average price of $6.04, for a total transaction of $18,790.44.
• On Monday, January 5th, Chidozie Ugwumba sold 5,869 shares of Clene stock. The shares were sold at an average price of $5.87, for a total transaction of $34,451.03.
• On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The shares were sold at an average price of $5.73, for a total transaction of $23,005.95.
• On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The stock was sold at an average price of $5.81, for a total value of $76,081.95.
• On Tuesday, December 30th, Chidozie Ugwumba sold 4,138 shares of Clene stock. The stock was sold at an average price of $6.03, for a total value of $24,952.14.
• On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The shares were sold at an average price of $5.95, for a total value of $48,171.20.
• On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The shares were sold at an average price of $6.27, for a total value of $42,830.37.
• On Friday, December 26th, Chidozie Ugwumba sold 3,350 shares of Clene stock. The shares were sold at an average price of $6.32, for a total value of $21,172.00.
• On Wednesday, December 24th, Chidozie Ugwumba sold 1,490 shares of Clene stock. The shares were sold at an average price of $6.27, for a total value of $9,342.30.
• On Monday, December 22nd, Chidozie Ugwumba sold 4,367 shares of Clene stock. The stock was sold at an average price of $6.54, for a total value of $28,560.18.

Clene Stock Up 7.0%

NASDAQ CLNN opened at $6.39 on Friday. Clene Inc. has a 52 week low of $2.28 and a 52 week high of $13.50. The firm has a market capitalization of $66.01 million, a price-to-earnings ratio of -1.88 and a beta of 0.87. The company has a fifty day moving average of $7.68 and a two-hundred day moving average of $6.41.

Clene (NASDAQ:CLNN) last released its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.06 million. Equities research analysts anticipate that Clene Inc. will post -5.19 EPS for the current year.

Institutional Trading of Clene

Several institutional investors and hedge funds have recently modified their holdings of CLNN. Scoggin Management LP boosted its holdings in shares of Clene by 75.1% in the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after purchasing an additional 107,250 shares during the period. Lunt Capital Management Inc. increased its holdings in Clene by 2.5% during the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after purchasing an additional 1,250 shares during the period. Jane Street Group LLC bought a new stake in Clene during the 2nd quarter valued at $47,000. Finally, Jones Financial Companies Lllp purchased a new stake in shares of Clene in the 3rd quarter worth $29,000. Institutional investors own 23.28% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on CLNN shares. UBS Group restated a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Clene in a report on Tuesday, October 14th. Benchmark restated a “buy” rating on shares of Clene in a report on Thursday, December 4th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Clene in a research report on Friday. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Clene currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).